Findings

What do systematic reviews say?

26 questions · 26 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 26.9%GRADE not reported 0 · 0%Very low 10 · 38.5%Low 8 · 30.8%Moderate 1 · 3.8%High 0 · 0%

Radioembolisation vs sorafenib monotherapy

All‐cause mortality at 1 year · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 360 participants
Very low

Radioembolisation vs sorafenib monotherapy

Health‐related quality of life · people with hepatocellular carcinoma

1 finding from 1 review

Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 360 participants
Very low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 1.25 [0.95, 1.64]
1 study · 517 participants
Low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 0.85 [0.74, 0.97]
1 study · 516 participants
Low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 506 participants
Low

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
HR 0.79 [0.64, 0.99]
1 study · 517 participants
Low